drugset / Trial / NCT04899115
VE303 for Treatment of Hepatic Encephalopathy (HE)
Phase 2
Completed
19 enrolled
Patricia Bloom
American Association for the Study of Liver Diseases · collabAmerican College of Gastroenterology · collabVedanta Biosciences, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy. Eligible participants will be enrolled and given oral antibiotics followed by 14 days of the study drug (placebo vs.VE303). There will be visits as well as other procedures to collect blood and stool samples, and have tests of your cognition (thinking) for this research study. The hypothesis is that VE303 will safely and effectively improve cognitive function in patients with a history of overt hepatic encephalopathy.
Timeline
- Start
- 2021-08-06
- Primary completion
- 2023-04-10
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VE303 | Other / unclassified | — | Oral |
| Background | Vancomycin | Other / unclassified | 125 mg | Oral |